Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Results: Significant improvements were observed in PASI, PGA, DLQI, and pruritus scores (p < 0.05). 25(OH)D3, serotonin, and kynurenic acid levels increased significantly, while IL-31 and IL-17 levels decreased and IL-13 levels increased; TNF-α, adiponectin, and quinolinic acid levels showed no significant changes.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Pregnant and breastfeeding women were also excluded from the study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Systemic Immunomodulatory Effects of Full-Body Blue Light Therapy in Psoriasis Vulgaris Patients

Study design awaiting verification · Journal of Clinical Medicine · 2026

Original publication title

Systemic Immunomodulatory Effects of Full-Body Blue Light Therapy in Psoriasis Vulgaris Patients

Daniel Nolberczak; Aleksandra Lesiak; Magdalena Sadowska; Igor Aleksander Bednarski; Natalia Bień; Joanna Narbutt

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives:

Psoriasis vulgaris is a chronic inflammatory skin condition with significant psychosocial burden. While phototherapy remains one of the most widely used treatment regimens, novel modalities like blue light therapy offer UV-free alternatives with potentially more favorable safety profiles, but their systemic immunomodulatory effects remain poorly understood. We aimed to evaluate the impact of full-body blue light irradiation on clinical outcomes and selected systemic biochemical and immunological markers in patients with mild-to-moderate psoriasis vulgaris.

Methods:

This preliminary study involved 21 patients (13 females, 8 males) with mild-to-moderate psoriasis vulgaris. Participants received ten sessions of full-body blue light therapy (453 nm, 40 mW/cm2, 30 min per session). Clinical assessments (PASI, PGA, DLQI, VAS, Pruritus Scale) and serum analyses of inflammatory (TNF-α, IL-13, IL-17, IL-31), metabolic (adiponectin, 25(OH)D3), and neuroimmune markers (serotonin, kynurenic acid, quinolinic acid) were performed pre: and post-treatment.

Results:

Significant improvements were observed in PASI, PGA, DLQI, and pruritus scores (p < 0.05). 25(OH)D3, serotonin, and kynurenic acid levels increased significantly, while IL-31 and IL-17 levels decreased and IL-13 levels increased; TNF-α, adiponectin, and quinolinic acid levels showed no significant changes. Counterintuitively, correlation analysis demonstrated a moderate positive association between changes in IL-13 and PASI improvement (r = 0.51, p = 0.02), while changes in other biochemical parameters were not significantly associated with clinical outcomes.

Conclusions:

Full-body blue light therapy resulted in significant clinical improvement accompanied by heterogeneous systemic immunometabolic changes. These findings suggest complex, pathway-specific immunomodulation, but this requires further investigation in larger controlled studies.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Psoriasis vulgaris is a chronic inflammatory skin condition with significant psychosocial burden. While phototherapy remains one of the most widely used treatment regimens, novel modalities like blue light therapy offer UV-free alternatives with potentially more favorable safety profiles, but their systemic immunomodulatory effects remain poorly understood. We aimed to evaluate the impact of full-body blue light irradiation on clinical outcomes and selected systemic biochemical and immunological markers in patients with mild-to-moderate psoriasis vulgaris.

Source: Background/Objectives:

Abstract: Results

Significant improvements were observed in PASI, PGA, DLQI, and pruritus scores (p < 0.05). 25(OH)D3, serotonin, and kynurenic acid levels increased significantly, while IL-31 and IL-17 levels decreased and IL-13 levels increased; TNF-α, adiponectin, and quinolinic acid levels showed no significant changes. Counterintuitively, correlation analysis demonstrated a moderate positive association between changes in IL-13 and PASI improvement (r = 0.51, p = 0.02), while changes in other biochemical parameters were not significantly associated with clinical outcomes.

Source: Results:

Abstract: Conclusions

Full-body blue light therapy resulted in significant clinical improvement accompanied by heterogeneous systemic immunometabolic changes. These findings suggest complex, pathway-specific immunomodulation, but this requires further investigation in larger controlled studies.

Source: Conclusions:
Authors’ abstract

Background/Objectives:

Psoriasis vulgaris is a chronic inflammatory skin condition with significant psychosocial burden. While phototherapy remains one of the most widely used treatment regimens, novel modalities like blue light therapy offer UV-free alternatives with potentially more favorable safety profiles, but their systemic immunomodulatory effects remain poorly understood. We aimed to evaluate the impact of full-body blue light irradiation on clinical outcomes and selected systemic biochemical and immunological markers in patients with mild-to-moderate psoriasis vulgaris.

Methods:

This preliminary study involved 21 patients (13 females, 8 males) with mild-to-moderate psoriasis vulgaris. Participants received ten sessions of full-body blue light therapy (453 nm, 40 mW/cm2, 30 min per session). Clinical assessments (PASI, PGA, DLQI, VAS, Pruritus Scale) and serum analyses of inflammatory (TNF-α, IL-13, IL-17, IL-31), metabolic (adiponectin, 25(OH)D3), and neuroimmune markers (serotonin, kynurenic acid, quinolinic acid) were performed pre: and post-treatment.

Results:

Significant improvements were observed in PASI, PGA, DLQI, and pruritus scores (p < 0.05). 25(OH)D3, serotonin, and kynurenic acid levels increased significantly, while IL-31 and IL-17 levels decreased and IL-13 levels increased; TNF-α, adiponectin, and quinolinic acid levels showed no significant changes. Counterintuitively, correlation analysis demonstrated a moderate positive association between changes in IL-13 and PASI improvement (r = 0.51, p = 0.02), while changes in other biochemical parameters were not significantly associated with clinical outcomes.

Conclusions:

Full-body blue light therapy resulted in significant clinical improvement accompanied by heterogeneous systemic immunometabolic changes. These findings suggest complex, pathway-specific immunomodulation, but this requires further investigation in larger controlled studies.

Publication and source details

Original title: Systemic Immunomodulatory Effects of Full-Body Blue Light Therapy in Psoriasis Vulgaris Patients

Daniel Nolberczak; Aleksandra Lesiak; Magdalena Sadowska; Igor Aleksander Bednarski; Natalia Bień; Joanna Narbutt

Journal of Clinical Medicine · 2026

* Correspondence: d.nolberczak@gmail.com© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. statutory activities of the Medical University of Lodzhttps://ror.org/02t4ekc95 503/1-064-01/503-11-001This research was funded by statutory activities of the Medical University of Lodz, no. 503/1-064-01/503-11-001.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:11:57.302526+00:00

DOI: 10.3390/jcm15135109 · PMC13362578